ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Jun 1, 2026, 11:16Ocima Richard Draza: Postpartum Hemorrhage – A Practical Step-by-Step Management Guide
-
Jun 1, 2026, 10:57Kyungjun Lim: How Will Future Mars Colonies Manage Their Supply Chains?
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership